These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26626719)

  • 1. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
    van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
    J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
    Govoni M; Poli G; Acerbi D; Santoro D; Cicirello H; Annoni O; Ružička J
    Pulm Pharmacol Ther; 2013 Apr; 26(2):249-55. PubMed ID: 23232039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
    Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
    J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
    Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
    J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
    van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
    J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.
    Westerman EM; Boer AH; Touw DJ; Brun PP; Roldaan AC; Frijlink HW; Heijerman HG
    J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):269-80. PubMed ID: 18759658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
    Ratjen F; Munck A; Kho P; Angyalosi G;
    Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
    Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
    Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.
    van Velzen AJ; Uges JWF; Heijerman HGM; Arets BGM; Nuijsink M; van der Wiel-Kooij EC; van Maarseveen EM; van Zanten GA; Pullens B; Touw DJ; Janssens HM
    Br J Clin Pharmacol; 2019 Sep; 85(9):1984-1993. PubMed ID: 31112621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.
    Griese M; Eismann C; Börner G; Denk O; Schierholz JM; Keller M; Mazurek H; Kappler M
    J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):185-92. PubMed ID: 23789705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
    Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
    J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
    Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G
    Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
    Hodson ME; Gallagher CG; Govan JR
    Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.